Current aspects of COVID-19 vaccine prophylaxis: big steps from laboratory to clinical practice
https://doi.org/10.51523/2708-6011.2021-18-4-1
Abstract
For more than a year and a half, the entire world has been experiencing the COVID-19 pandemic. Only the development of safe and effective vaccines may make the most significant changes in the fight against this infection. The World Health Organization (WHO) and its partners are contributing to accelerated development of vaccines because it is the vaccination along with social distancing and the use of personal protective equipment that is an effective way to prevent the coronavirus disease. This review covers general characteristics of vaccines registered or approved by at least one national regulator, the risks and side effects of the vaccines, as well as approaches to assess the effectiveness of COVID-19 vaccination.
About the Authors
D. V. Grinko
Center for Examinations and Tests in Health Service
Belarus
Belarus
Dmitry V. Grinko, Director
Minsk
D. V. Moiseev
Center for Examinations and Tests in Health Service
Belarus
Belarus
Dmitry V. Moiseev, PharmD, Head of the Republican Control and Analysis Laboratory
Minsk
E. V. Voropaev
Gomel State Medical University
Belarus
Belarus
Evgenii V. Voropaev, PhD (Med), Associate Professor, Vice-Rector in charge of scientific work
Gomel
I. O. Stoma
Gomel State Medical University
Belarus
Belarus
Igor O. Stoma, DMedSc, Associate Professor, Rector
Gomel
References
1. The Eurasian Economic Commission (EEC) [Electronic resource]. [date of access 2021 September 13]. Available from: https://eec.eaeunion.org/comission/about/ (In Russ.).
2. Ministry of Health of the Republic of Belarus [Electronic resource]. [date of access 2021 September 13]. Available from: http://minzdrav.gov.by/ru/ministerstvo/ (In Russ.).
3. Center for Examinations and Tests in Health Service Republican Unitary Enterprise [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.rceth.by/ (In Russ.)
4. Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, Usova SV, Danilenko ED, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity. 2021;11(2):283-296. DOI: https://doi.org/10.15789/2220-7619-ASB-1699
5. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 Jul;26(7):1033-1036. DOI: https://doi.org/10.1038/s41591-020-0913-5
6. Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. The Lancet Regional Health – Europe. 2021 Dec;11:100241. DOI: https://doi.org/10.1016/j.lanepe.2021.100241
7. Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol. 2008 Dec 15;168(12):1343-1352. DOI: https://doi.org/10.1093/aje/kwn259
8. Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. DOI: https://doi.org/10.15585/mmwr.mm7044e1
9. Chen J, Miao L, Li JM, Li YY, Zhu QY, Zhou CL, Fang HQ, Chen HP. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol. 2005 Oct 21;11(39):6159-6164. DOI: https://doi.org/10.3748/wjg.v11.i39.6159
10. COVID-19 vaccine tracker and landscape [Electronic resource]. World Health Organization (WHO). [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
11. Xu R, Shi M, Li J, Song P, Li N. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. Front Bioeng Biotechnol. 2020 Jul 30;8:862. DOI: https://doi.org/10.3389/fbioe.2020.00862
12. Gavi. The Gavi COVAX AMC: an investment opportunity [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.gavi.org/investment-opportunity-gavi-covax-amc
13. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013 Nov 19;31(48):5634-5642. DOI: https://doi.org/10.1016/j.vaccine.2013.07.006
14. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. DOI: https://doi.org/10.1016/S1473-3099(20)30773-8
15. Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Gavrilova EV, Danilenko ED, Imatdinov IR, Maksyutov RA, Nechaeva EA, Popova AY, Pyankov OV, Pyankova OG, Susloparov IM. Vaccine composition against coronavirus infection COVID-19 [Electronic resource]. Patent of Russian Federation N 2743595. 20.02.2020. [date of access 2021 September 13]. Available from: https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2743595&TypeFile=html (In Russ.).
16. The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores [Electronic resource]. ClinicalTrials.gov. [date of access 2021 September 13]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT05057923
17. Understanding Viral Vector COVID-19 Vaccines. [Electronic resource]. Centers for Disease Control and Prevention [date of access 2021 September 13]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html
18. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516-5276. DOI: https://doi.org/10.1038/s41586-020-2798-3
19. Rattanapisit K, Shanmugaraj B, Manopwisedjaroen S, Purwono PB, Siriwattananon K, et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. Sci Rep. 2020 Oct 19;10(1):17698. DOI: https://doi.org/10.1038/s41598-020-74904-1
20. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305-306. DOI: https://doi.org/10.1038/d41573-020-00073-5
21. Velázquez RF, Linhares AC, Muñoz S, Seron P, Lorca P, DeAntonio R, Ortega-Barria E. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatr. 2017 Jan 13;17(1):14. DOI: https://doi.org/10.1186/s12887-016-0771-y
22. Wang H, Zhang Y, Huang B, Deng W, Quan Y, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 Aug 6;182(3):713-721.e9. DOI: https://doi.org/10.1016/j.cell.2020.06.008
23. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010 Jun 1;201(11):1607-1610. DOI: https://doi.org/10.1086/652404
24. WHO Target Product Profiles for COVID-19 Vaccines. [Electronic resource].World Health Organization (WHO). [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines
25. World Health Organization (WHO) [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
26. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479-488. DOI: https://doi.org/10.1016/S0140-6736(20)31605-6
Review
For citations:
Grinko D.V., Moiseev D.V., Voropaev E.V., Stoma I.O. Current aspects of COVID-19 vaccine prophylaxis: big steps from laboratory to clinical practice. Health and Ecology Issues. 2021;18(4):5-16. (In Russ.) https://doi.org/10.51523/2708-6011.2021-18-4-1
Views: 582
Email this article 